Table 4: Cox proportional hazard analysis.

CharacteristicRegression estimate
(B)
S.E.Relative risk
Exp(B) (95% CI)
P value

Donor’s age (years)
 <301
 31–40−0.0490.0970.952 (0.788, 1.150) 0.609
 41–50 0.3260.1091.385 (1.120, 1.714) 0.003
 >50 0.4870.1451.628 (1.224, 2.164)<0.001
Genetic considerations
 (i) HLA-ID siblings1
 (ii) 1-haplotype MM (R)0.0590.2031.099 (0.739, 1.635) 0.641
 (iii) 2-haplotype MM (R + UR)0.4040.2111.498 (0.990, 2.267)0.056
No. of acute rejection episodes (during first 3 months)
 (i) No 1
 (ii) One0.7790.1302.218 (1.689, 2.814)<0.001
 (iii) ≥21.5590.1314.754 (3.737, 6.141)<0.001
Total steroid dose (during first 3 months)
 <5 gm1
 5–10 gm−0.3630.1000.696 (0.572, 0.846)0.001
  >10 gm−0.2940.1350.745 (0.572, 0.972)0.030
Primary immunosuppression
 (i) Aza-based (dual therapy)1
 (ii) CsA-based (dual therapy)−0.0220.1390.978 (0.744, 1.285)0.872
 (iii) CsA-based (triple therapy) −0.2340.1140.791 (0.633, 0.989)0.039
 (iv) Tacrolimus-based (triple therapy)−0.6860.2280.504 (0.322, 0.787)0.003